| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) (NCT07557420) | Alexion Pharmaceuticals, Inc. | 2026-08-31 |
| Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) (NCT07596784) | Alexion Pharmaceuticals, Inc. | 2026-07-30 |
| Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (NCT06015750) | Alexion Pharmaceuticals, Inc. | 2026-07-29 |
| Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants (NCT07352423) | Alexion Pharmaceuticals, Inc. | 2026-03-26 |
| A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab (NCT07221838) | Alexion Pharmaceuticals, Inc. | 2026-03-04 |
| Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data (NCT07413250) | Alexion Pharmaceuticals, Inc. | 2026-01-14 |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS (NCT07308574) | Alexion Pharmaceuticals, Inc. | 2025-12-19 |
| Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (NCT07160608) | Alexion Pharmaceuticals, Inc. | 2025-11-26 |
| ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (NCT07037420) | Alexion Pharmaceuticals, Inc. | 2025-10-28 |
| ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy (NCT07218887) | Alexion Pharmaceuticals, Inc. | 2025-10-24 |
| Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers (NCT07306949) | Alexion Pharmaceuticals, Inc. | 2025-10-01 |
| Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) (NCT07157787) | Alexion Pharmaceuticals, Inc. | 2025-09-19 |
| A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. (NCT07081646) | Alexion Pharmaceuticals, Inc. | 2025-08-18 |
| Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis (NCT06449001) | Alexion Pharmaceuticals, Inc. | 2025-08-11 |
| Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis (NCT06967480) | Alexion Pharmaceuticals, Inc. | 2025-07-31 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN (NCT07024563) | Alexion Pharmaceuticals, Inc. | 2025-06-14 |
| Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation (NCT06830798) | Alexion Pharmaceuticals, Inc. | 2025-05-19 |
| Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation (NCT06744647) | Alexion Pharmaceuticals, Inc. | 2025-03-07 |
| A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT). (NCT07732361) | Alexion Pharmaceuticals, Inc. | 2025-01-22 |
| Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD (NCT06724809) | Alexion Pharmaceuticals, Inc. | 2025-01-16 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG (NCT06764160) | Alexion Pharmaceuticals, Inc. | 2025-01-06 |
| Study of Ultomiris® (Ravulizumab) Safety in Pregnancy (NCT06312644) | Alexion Pharmaceuticals, Inc. | 2024-12-16 |
| PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis (NCT06607627) | Alexion Pharmaceuticals, Inc. | 2024-11-13 |
| PK Study of Gefurulimab SC in Healthy Chinese Adult Participants (NCT06677138) | Alexion Pharmaceuticals, Inc. | 2024-10-28 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT06578949) | Alexion Pharmaceuticals, Inc. | 2024-10-10 |
| Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP (NCT06079359) | Alexion Pharmaceuticals, Inc. | 2024-05-14 |
| Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (NCT06079372) | Alexion Pharmaceuticals, Inc. | 2024-04-02 |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (NCT06291376) | Alexion Pharmaceuticals, Inc. | 2024-03-29 |
| Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies (NCT05966467) | Alexion Pharmaceuticals, Inc. | 2024-02-01 |
| Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine (NCT06071442) | Alexion Pharmaceuticals, Inc. | 2024-01-17 |
| A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults (NCT06173596) | Alexion Pharmaceuticals, Inc. | 2024-01-10 |
| Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa (NCT06079281) | Alexion Pharmaceuticals, Inc. | 2024-01-03 |
| A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants (NCT06208488) | Alexion Pharmaceuticals, Inc. | 2023-11-22 |
| Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China (NCT05876351) | Alexion Pharmaceuticals, Inc. | 2023-07-14 |
| Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China (NCT05886244) | Alexion Pharmaceuticals, Inc. | 2023-07-05 |
| Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis (NCT05644561) | Alexion Pharmaceuticals, Inc. | 2023-06-24 |
| Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism (NCT05778071) | Alexion Pharmaceuticals, Inc. | 2023-06-07 |
| Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants (NCT05751642) | Alexion Pharmaceuticals, Inc. | 2023-04-19 |
| A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants (NCT06160414) | Alexion Pharmaceuticals, Inc. | 2023-04-12 |
| ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE (NCT05746559) | Alexion Pharmaceuticals, Inc. | 2023-04-06 |
| A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants (NCT05780645) | Alexion Pharmaceuticals, Inc. | 2023-03-15 |
| Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease (NCT05565092) | Alexion Pharmaceuticals, Inc. | 2023-02-22 |
| Potential Drug Interaction Between ALXN2040 and Rosuvastatin (NCT05708573) | Alexion Pharmaceuticals, Inc. | 2023-02-01 |
| Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis (NCT05556096) | Alexion Pharmaceuticals, Inc. | 2022-11-21 |
| A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH (NCT05389449) | Alexion Pharmaceuticals, Inc. | 2022-10-28 |
| A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) (NCT05981092) | Alexion Pharmaceuticals, Inc. | 2022-10-14 |
| Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics (NCT05578846) | Alexion Pharmaceuticals, Inc. | 2022-10-13 |
| Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants (NCT05428696) | Alexion Pharmaceuticals, Inc. | 2022-09-12 |
| A Prospective Sub-Study of the Global Hypophosphatasia Registry (NCT05234567) | Alexion Pharmaceuticals, Inc. | 2022-08-25 |
| Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants (NCT05501717) | Alexion Pharmaceuticals, Inc. | 2022-08-16 |
| Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy (NCT05506254) | Alexion Pharmaceuticals, Inc. | 2022-07-15 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria (NCT05314231) | Alexion Pharmaceuticals, Inc. | 2022-06-29 |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD (NCT05346354) | Alexion Pharmaceuticals, Inc. | 2022-06-23 |
| Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT05274633) | Alexion Pharmaceuticals, Inc. | 2022-06-17 |
| Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis (NCT05218096) | Alexion Pharmaceuticals, Inc. | 2022-04-27 |
| Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants (NCT05307978) | Alexion Pharmaceuticals, Inc. | 2022-04-12 |
| Study of ALXN2050 in Participants With Hepatic Impairment (NCT05259085) | Alexion Pharmaceuticals, Inc. | 2022-04-07 |
| Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (NCT05097989) | Alexion Pharmaceuticals, Inc. | 2022-01-14 |
| Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants (NCT05202145) | Alexion Pharmaceuticals, Inc. | 2022-01-11 |
| Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis (NCT04982289) | Alexion Pharmaceuticals, Inc. | 2022-01-01 |
| Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis (NCT04999020) | Alexion Pharmaceuticals, Inc. | 2021-11-19 |
| Study of ALXN1850 in Participants With Hypophosphatasia (HPP) (NCT04980248) | Alexion Pharmaceuticals, Inc. | 2021-09-28 |
| Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease (NCT05047523) | Alexion Pharmaceuticals, Inc. | 2021-09-13 |
| A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT05019521) | Alexion Pharmaceuticals, Inc. | 2021-08-23 |
| Study in Adult and Pediatric Patients With HSCT-TMA (NCT04970004) | Alexion Pharmaceuticals, Inc. | 2021-07-12 |
| Study of ALXN2050 in Healthy Adult Participants of Japanese Descent (NCT04952545) | Alexion Pharmaceuticals, Inc. | 2021-07-09 |
| Study of ALXN2050 in Participants With Renal Impairment (NCT04623710) | Alexion Pharmaceuticals, Inc. | 2021-07-08 |
| ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia (NCT04256148) | Alexion Pharmaceuticals, Inc. | 2021-07-01 |
| Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger (NCT04743804) | Alexion Pharmaceuticals, Inc. | 2021-06-29 |
| Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery (NCT04233073) | Alexion Pharmaceuticals, Inc. | 2021-06-27 |
| Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants (NCT04933682) | Alexion Pharmaceuticals, Inc. | 2021-06-07 |
| Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants (NCT04958135) | Alexion Pharmaceuticals, Inc. | 2021-05-30 |
| Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab (NCT04320602) | Alexion Pharmaceuticals, Inc. | 2021-04-14 |
| Study of Radiolabeled ALXN2050 in Healthy Adult Males (NCT04609670) | Alexion Pharmaceuticals, Inc. | 2021-04-12 |
| A Study of ALXN1830 in Healthy Adult Participants (NCT04730804) | Alexion Pharmaceuticals, Inc. | 2021-03-17 |
| A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome (NCT04752566) | Alexion Pharmaceuticals, Inc. | 2021-03-08 |
| Bioavailability Study of 2 Oral Formulations of ALXN1840 (NCT04610580) | Alexion Pharmaceuticals, Inc. | 2021-01-31 |
| Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (NCT04564339) | Alexion Pharmaceuticals, Inc. | 2021-01-19 |
| Study of ALXN1820 in Healthy Adult Participants (NCT04631562) | Alexion Pharmaceuticals, Inc. | 2021-01-13 |
| Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) (NCT04469465) | Alexion Pharmaceuticals, Inc. | 2020-12-16 |
| A Study of the Cardiac Effects of ALXN2050 in Healthy Adults (NCT04660890) | Alexion Pharmaceuticals, Inc. | 2020-12-12 |
| Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant (NCT04543591) | Alexion Pharmaceuticals, Inc. | 2020-12-10 |
| Study of Ravulizumab in Pediatric Participants With HSCT-TMA (NCT04557735) | Alexion Pharmaceuticals, Inc. | 2020-12-07 |
| Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 (NCT04422431) | Alexion Pharmaceuticals, Inc. | 2020-12-02 |
| A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM (NCT04622046) | Alexion Pharmaceuticals, Inc. | 2020-11-13 |
| Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants (NCT04526210) | Alexion Pharmaceuticals, Inc. | 2020-10-21 |
| Study of the Metabolism of Danicopan in Healthy Adults (NCT04609696) | Alexion Pharmaceuticals, Inc. | 2020-10-20 |
| Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 (NCT04573309) | Alexion Pharmaceuticals, Inc. | 2020-09-07 |
| AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism (NCT05239221) | Alexion Pharmaceuticals, Inc. | 2020-09-07 |
| A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) (NCT04504825) | Alexion Pharmaceuticals, Inc. | 2020-08-25 |
| Study of Danicopan in Participants of Japanese Descent (NCT04451434) | Alexion Pharmaceuticals, Inc. | 2020-08-17 |
| A Study of the Cardiac Effects of ALXN1840 in Healthy Adults (NCT04560816) | Alexion Pharmaceuticals, Inc. | 2020-07-24 |
| Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. (NCT04526197) | Alexion Pharmaceuticals, Inc. | 2020-07-07 |
| Copper Balance in Healthy Participants Administered ALXN1840 (NCT04594252) | Alexion Pharmaceuticals, Inc. | 2020-07-01 |
| A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants (NCT04551586) | Alexion Pharmaceuticals, Inc. | 2020-06-26 |
| Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia (NCT04369469) | Alexion Pharmaceuticals, Inc. | 2020-05-10 |
| Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease (NCT04189315) | Alexion Pharmaceuticals, Inc. | 2020-04-01 |
| An Efficacy and Safety Study of Ravulizumab in ALS Participants (NCT04248465) | Alexion Pharmaceuticals, Inc. | 2020-03-30 |
| A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis (NCT04304144) | Alexion Pharmaceuticals, Inc. | 2020-03-18 |
| A Study of the Effects of Food and Age on Danicopan (NCT04551599) | Alexion Pharmaceuticals, Inc. | 2020-02-21 |